Last update Nov. 9, 2014
Low Risk
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
モルニフルマート belongs to this group or family:
Main tradenames from several countries containing モルニフルマート in its composition:
Variable | Value | Unit |
---|---|---|
Molecular weight | 282 | daltons |
Protein Binding | 90 | % |
VD | 0.12 | l/Kg |
Tmax | 2 | hours |
T½ | 4 - 6 | hours |
M/P ratio | 0.01 | - |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Active metabolite of Morniflumate.
At latest update, relevant information on excretion into breast milk was not found.
Due to a high serum-protein-binding capacity, excretion of Rabeprazole into breast milk in significant levels is unlikely.
Based on data offered by the manufacturer, excretion into breast milk is minimal, with a concentration in the milk which is one-hundredth less than plasma level.
Nevertheless, it would be prudent the use of anti-inflammatory drugs known to be safe while breastfeeding.